References for this Review were identified through searches of PubMed from 1966 until August, 2007, with the terms “medulloblastoma”, “pediatric”, and “brain tumour”. Articles were also identified through searches of the authors' own files. Only papers published in English were reviewed.
ReviewMedulloblastoma in childhood: new biological advances
Introduction
Medulloblastoma is the most common brain tumour in children. The tumour is thought to arise from neural stem cell precursors in the granular cell layer of the cerebellum, although there is debate about the exact cellular origin. Patients are currently divided into stratification groups on the basis of age, the degree of resection, and disease dissemination. Standard treatment includes surgery, chemotherapy, and depending on the age of the patient, radiation therapy; however, greater understanding of the molecular signals in the development and proliferation of medulloblastoma will probably change the stratification and management of the disease. This Review will focus on the current means of diagnosis and treatment, which have led to improved survival rates but a disappointingly high incidence of sequelae. We also provide an overview of the molecular biology of medulloblastoma and its potential to dramatically alter risk stratification and future therapy. Advances in understanding the signalling pathways in neuro-oncogenesis will, hopefully, lead to more effective and less toxic targeted therapy.
Section snippets
Epidemiology
The Central Brain Tumor Registry of the United States reports that the incidence of medulloblastoma in patients up to 19 years old ranges from 0·48 (girls) to 0·75 (boys) per 100 000 patient-years and accounts for 16% of all paediatric brain tumours; 40% of all cerebellar tumours in childhood are medulloblastoma. Medulloblastoma occurs bimodally with peak incidences between 3 and 4 years and 8 and 9 years of age. Approximately 10–15% of medulloblastomas are diagnosed in infancy.1 Although
Clinical presentation
Patients with medulloblastoma frequently present with signs of intracranial pressure related to obstructive hydrocephalus due to tumour growth and compression of the fourth ventricle. Preceding signs of intracranial pressure include an increase in head circumference in children whose fontanelles are still open, and early morning headache with vomiting, irritability, and lethargy. Because many paediatric medulloblastomas arise in the cerebellar midline, axial instability can be seen, which
Neuroimaging
CT is usually the first-line neuroimaging modality for patients with posterior fossa tumours because of its availability in an emergency setting. A typical feature of medulloblastoma seen with CT is a midline, homogeneous, contrast-enhancing cerebellar vermian mass.9 However, this radiographic feature is seen in only 30–55% of patients. Atypical CT features include cystic changes, hypodense non-enhancing lesions, and calcifications.10, 11
MRI has helped with the diagnosis of childhood
Staging and risk stratification
Staging and subsequent risk stratification are crucial in the management of medulloblastoma. Current staging classification requires analysis of the CSF and MRI of the brain and entire spine with gadolinium. CSF from the lumbar region is preferred because it is more sensitive than ventricular fluid for detecting disseminated disease.30 CSF should be obtained from the lumbar region 2 weeks postoperatively to avoid the false-positive cytology from the initial resection. Assessment of the CSF for
Surgery
Surgical resection of medulloblastoma is a fundamental part of treatment that has led to improved survival in randomised trials, particularly in children with localised disease.39, 40 Depending on the location and extent of the tumour, a ventricular shunt or third ventriculostomy might be needed emergently before resection to relieve increased intracranial pressure secondary to obstruction at the level of the foramen of Luschka, foramen of Magendie, or aqueduct of Sylvius. A sample of CSF to
Diagnosis and management of disease relapse
Relapses of medulloblastoma occur, and in patients who are treated with both radiotherapy and chemotherapy more than half of relapses have a component of disseminated disease.49, 60 Relapses occur earlier in children; nearly 75% of relapses in children are seen within 2 years. The median time to recurrence for adults is 26 months, and nearly a third of relapses occur more than 5 years after initial therapy.2
Relapse is most commonly diagnosed by neuroimaging; occasionally, clinical progression
Long-term treatment sequellae
Because multimodal therapies improve survival, a host of long-term neurological effects are being reported. In many cases, the location and extent of the metastases can contribute to the deleterious effects, but, inevitably, treatment with radiation and chemotherapy also have long-term consequences. Neurocognitive difficulties are one of the most pervasive of all long-term effects and occur across all age groups.72 Despite receiving reduced doses of intracranial radiation, children younger than
Controversies in the management of medulloblastoma
Although many of the developments in the management of children with medulloblastoma are the result of well performed, prospective multi-institutional randomised trials, areas of controversy remain. One of the most pressing is how best to incorporate the new biological understanding of the disease into everyday management. Compelling evidence exists that certain biological parameters are correlated with disease control; however, there is no consensus on which parameters or combination of
Molecular biology of medulloblastoma
During the past decade, our understanding of the molecular basis of medulloblastoma formation and progression has greatly improved. Research into medulloblastoma has focused on two areas. The first is understanding the pathogenesis. Medulloblastoma, although not conclusively established, has been postulated to arise from the two germinomal zones of the cerebellum: the ventricular zone, which contains multipotentional stem progenitors, for classic and midline tumours, and the external granular
Future directions
Although much progress has been made in the diagnosis and treatment of childhood medulloblastoma, much work still needs to be done. Probably the most useful and exciting progress has been in understanding and classifying the molecular biology of medulloblastoma. As the mechanisms of signal transduction in neuro-oncogenesis are elucidated, more specifically targeted therapies can be developed. Furthermore, a greater understanding of the genetics of medulloblastoma will enable more sophisticated
Search strategy and selection criteria
References (108)
- et al.
Current treatment of medulloblastoma: recent advances and future challenges
Semin Oncol
(2004) - et al.
Magnetic resonance spectroscopy suggests key differences in the metastatic behaviour of medulloblastoma
Eur J Cancer
(2007) - et al.
Mitotic percentage index: a new prognostic factor for childhood medulloblastoma
Eur J Cancer
(1997) - et al.
Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome
Eur J Cancer
(2006) - et al.
Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children
Lancet Oncol
(2005) - et al.
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial
Lancet Oncol
(2006) - et al.
Treatment of high-risk medulloblastomas in children above the age of 3 years: a SFOP study
Eur J Cancer
(2006) - et al.
Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma)
Int J Radiat Oncol Biol Phys
(1996) - et al.
A pilot study of pre-irradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma
Int J Radiat Oncol Biol Phys
(2004) - et al.
Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol
Int J Radiat Oncol Biol Phys
(2005)
Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study
Int J Radiat Oncol Biol Phys
Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy
Eur J Cancer
Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91
Int J Radiat Oncol Biol Phys
Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP)
Int J Radiat Oncol Biol Phys
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours
Eur J Cancer
In search of the medulloblast: neural stem cells and embryonal brain tumors
Neurosurg Clin N Am
What's new in neuro-oncology? Recent advances in medulloblastoma
Eur J Paediatr Neurol
Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−) p53(−/−) mice
Cancer Cell
Adult medulloblastoma: prognostic factors and patterns of relapse
Neurosurgery
The molecular basis of Turcot's syndrome
N Engl J Med
Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patients' age and extent of disease on prognosis
J Neurosurg
The value of myelography in the management of childhood medulloblastoma
Cancer
Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis?
Cancer
Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma
Cancer
CT findings of medulloblastoma
Childs Brain
Paediatric medulloblastoma: atypical CT features at presentation in the SIOP II trial
Neuroradiology
Uncommon presentation of medulloblastoma
Childs Nerv Syst
MRI of medulloblastoma in adults
Neuroradiology
MRI features of primary, secondary and metastatic medulloblastoma
Eur Radiol
Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to non-invasive differential diagnosis with cerebellar astrocytoma
Neurosurgery
[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma
Neurosurgery
Evaluation of single photon emission computerised tomography (SPECT) using Tc99m-tetrofosmin as a diagnostic modality for recurrent posterior fossa tumours
J Postgrad Med
Incorporating functional mr imaging into diffusion tensor tractography in the preoperative assessment of the corticospinal tract in patients with brain tumors
Am J Neuroradiol
Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: correlation with IQ
Neuro Oncol
Diffusion tensor magnetic resonance imaging finding of discrepant fractional anisotropy between the frontal and parietal lobes after whole-brain irradiation in childhood medulloblastoma survivors: reflection of regional white matter radiosensitivity?
Int J Radiat Oncol Biol Phys
Medulloblastoma
A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression
Mod Pathol
Differentiation in the medulloblastoma. A histological and immunohistochemical study
Acta Neuropathol (Berl)
Tumors of the Central Nervous System. Atlas of Tumor Pathology
Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands
Arch Pathol Lab Med
“Desmoplastic” versus “classic” medulloblastoma: comparison of DNA content, histopathology and differentiation
Virchows Arch A Pathol Anat Histopathol
Large-cell medulloblastomas. A distinct variant with highly aggressive behavior
Am J Surg Pathol
“Large cell/anaplastic” medulloblastomas: a pediatric oncology group study
J Neuropathol Exp Neurol
Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors
J Clin Oncol
Medulloblastoma: present concepts of stratification into risk groups
Pediatr Neurosurg
Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression
J Neurooncol
MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group
Arch Pathol Lab Med
MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma
Clin Cancer Res
Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior
Acta Neuropathol
Cited by (229)
Nucleic acid therapy in pediatric cancer
2022, Pharmacological ResearchCitation Excerpt :By administrating with multimodality therapy, the 5-year event-free survival rate in non-disseminated medulloblastoma with average risk could reach approximately 90%, while the high-risk group only has up to 65% survival rate. Though patients with medulloblastoma might survive from multimodality therapy, they still face the risk of long-term sequelae associated with the neurological effects of the tumor, surgery, or radiotherapy, as well as the side effects of chemotherapy [188]. The knockdown of AMBRA1 resulted in the reduction of stemness, proliferation, and migration of medulloblastoma by suppressing the MYC/AMBRA1/STAT3 signaling [189].
The role of m6A modification in pediatric cancer
2022, Biochimica et Biophysica Acta - Reviews on CancerIdentification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma
2021, Biochemical PharmacologyThe 100 most cited papers about medulloblastomas
2021, Interdisciplinary Neurosurgery: Advanced Techniques and Case ManagementEpigenetic pathways and plasticity in brain tumors
2020, Neurobiology of DiseaseCitation Excerpt :Although survival benefit occurs for some patients after standard-of-care treatment(Northcott et al., 2017; Parsons et al., 2011), several deficits persist. Treatment sequalae include neurocognitive impairments, mutism, and hearing loss as well as secondary malignancies that arise (Crawford et al., 2007; Neglia et al., 2006). Importantly, some patients are resistant to conventional therapy (Zhukova et al., 2013; Tabori et al., 2010; Schwalbe et al., 2017).